PARD3

Across TCGA pan-cancer cohorts, PARD3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PARD3 data layer compared with 29 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PARD3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PARD3 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where PARD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.234	0.821	.009	22	view →
CCRCC	OS	Median	All	0.739	0.934	.003	14	view →
LSCC	DFS	Tertile	All	1.000	0.883	.008	6	view →
HNSC	DFS	Quartile	II,III,IV	0.915	1.000	.037	2	view →
UCEC	DFS	Median	II,III,IV	0.826	1.000	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PARD3–LUAD (DFS)

Open the LUAD breakdown →